Aim:Helicobacter pylori-naïve gastric cancers(GCs) have not been well documented. We aimed to characterize early H. pylori-naïve GCs. Subjects and Methods: Of 666 patients with GC resected by endoscopic submucosal dissection, H. pylori-naïve patients were extracted according to the definition: no H. pylori eradication history, negative for serum H. pylori-antibody and current H. pylori-infection tests, and no gastric atrophy by pepsinogen (PG) test, endoscopy, and histology. Results: It was found that 16 GCs were H. pylori-naïve, and classified into undifferentiated and differentiated type adenocarcinoma. All 9 undifferentiated type GCs were pale, depressed, mucosal pure signet ring cell adenocarcinoma except one of them and 7 differentiated type GCs were classified into 3 fundic gland type GCs and 4 foveolar type GCs. All fundic gland type GCs positive for PG-1 were cardia small submucosal tumor (SMT)-like protrusions with dilated vessels on the surface. All 4 foveolar type GCs were composed of dysplastic clear cells resembling foveolar epithelium, negative for PG-1 but positive for mucin 6 (MUC6) and MUC5AC. Endoscopically, all were laterally spreading elevations with papillary or villous surface. Conclusions:H. pylori-naïve GCs were infrequent at 2.5%, and classified into 3 types: a small pale depression of signet ring cell adenocarcinoma, a small SMT-like protrusion of fundic gland type GC, and a large laterally spreading elevation of foveolar type GC.

Journal Section:
Original Paper
Keywords:
Helicobacter pylori-naïve early gastric cancer, Foveolar type adenocarcinoma, Fundic gland type adenocarcinoma, Pure signet ring cell adenocarcinoma
1.
Correa P: Helicobacter pylori and gastric carcinogenesis. Am J Surg Pathol 1995; 19:S37–S43.
[PubMed]
2.
Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7–14 June 1994. IARC Monogr Eval Carcinog Risks Hum 1994; 61: 1–241.
[PubMed]
3.
Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ: Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 345: 784–789.
[PubMed]
https://doi.org/10.1056/NEJMoa001999
4.
Fukase K, Kato M, Kikuchi S, Inoue K, Uemura N, Okamoto S, Terao S, Amagai K, Hayashi S, Asaka M: Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 2008; 372: 392–397.
[PubMed]
https://doi.org/10.1016/S0140-6736(08)61159-9
5.
Kato S, Matsukura N, Tsukada K, Matsuda N, Mizoshita T, Tsukamoto T, Tatematsu M, Sugisaki Y, Naito Z, Tajiri T: Helicobacter pylori infection-negative gastric cancer in Japanese hospital patients: incidence and pathological characteristics. Cancer Sci 2007; 98: 790–794.
[PubMed]
https://doi.org/10.1111/j.1349-7006.2007.00478.x
6.
Kakinoki R, Kushima R, Matsubara A, Saito Y, Okabe H, Fujiyama Y, Hattori T: Re-evaluation of histogenesis of gastric carcinomas: a comparative histopathological study between Helicobacter pylori-negative and H. pylori-positive cases. Dig Dis Sci 2009; 54: 614–620.
[PubMed]
https://doi.org/10.1007/s10620-008-0389-5
7.
Marrelli D, Pedrazzani C, Berardi A, Corso G, Neri A, Garosi L, Vindigni C, Santucci A, Figura N, Roviello F: Negative Helicobacter pylori status is associated with poor prognosis in patients with gastric cancer. Cancer 2009; 115: 2071–2080.
[PubMed]
https://doi.org/10.1002/cncr.24253
8.
Matsuo T, Ito M, Takata S, Tanaka S, Yoshihara M, Chayama K: Low prevalence of Helicobacter pylori-negative gastric cancer among Japanese. Helicobacter 2011; 16: 415–419.
[PubMed]
https://doi.org/10.1111/j.1523-5378.2011.00889.x
9.
Yoon H, Kim N, Lee HS, Shin CM, Park YS, Lee DH, Jung HC, Song IS: Helicobacter pylori-negative gastric cancer in South Korea: incidence and clinicopathologic characteristics. Helicobacter 2011; 16: 382–388.
[PubMed]
https://doi.org/10.1111/j.1523-5378.2011.00859.x
10.
Ono S, Kato M, Suzuki M, Ishigaki S, Takahashi M, Haneda M, Mabe K, Shimizu Y: Frequency of Helicobacter pylori-negative gastric cancer and gastric mucosal atrophy in a Japanese endoscopic submucosal dissection series including histological, endoscopic and serological atrophy. Digestion 2012; 86: 59–65.
[PubMed]
https://doi.org/10.1159/000339176
11.
Kwak HW, Choi IJ, Cho SJ, Lee JY, Kim CG, Kook MC, Ryu KW, Kim YW: Characteristics of gastric cancer according to Helicobacter pylori infection status. J Gastroenterol Hepatol 2014; 29: 1671–1677.
[PubMed]
https://doi.org/10.1111/jgh.12605
12.
Dixon MF: Gastrointestinal epithelial neoplasia: vienna revisited. Gut 2002; 51: 130–131.
[PubMed]
13.
Kimura K, Takemoto T: An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy 1969; 3: 87–97.
https://doi.org/10.1055/s-0028-1098086
14.
Japanese Gastric Cancer Association: Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer 2011; 14: 101–112.
[PubMed]
https://doi.org/10.1007/s10120-011-0041-5
15.
Yagi K, Nakamura A, Sekine A: Characteristic endoscopic and magnified endoscopic findings in the normal stomach without Helicobacter pylori infection. J Gastroenterol Hepatol 2002; 17: 39–45.
[PubMed]
https://doi.org/10.1046/j.1440-1746.2002.02665.x
16.
Iijima K, Abe Y, Kikuchi R, Koike T, Ohara S, Sipponen P, Shimosegawa T: Serum biomarker tests are useful in delineating between patients with gastric atrophy and normal, healthy stomach. World J Gastroenterol 2009; 15: 853–859.
[PubMed]
https://doi.org/10.3748/wjg.15.853
17.
Sasaki A, Kitadai Y, Ito M, Tanaka S, Yoshihara M, Haruma K, Chayama K: Mucin phenotype and background mucosa of intramucosal differentiated-type adenocarcinoma of the stomach. Oncology 2004; 66: 379–387.
[PubMed]
https://doi.org/10.1159/000079486
18.
Horiuchi Y, Fujisaki J, Yamamoto N, Shimizu T, Miyamoto Y, Tomida H, Taniguchi C, Morishige K, Omae M, Ishiyama A, Yoshio T, Hirasawa T, Yamamoto Y, Tsuchida T, Igarashi M, Nakajima T, Takahashi H: Biological behavior of the intramucosal Helicobacter pylori-negative undifferentiated-type early gastric cancer: comparison with Helicobacter pylori-positive early gastric cancer. Gastric Cancer 2016; 19: 160–165.
[PubMed]
https://doi.org/10.1007/s10120-014-0452-1
19.
Horiuchi Y, Fujisaki, Ishizuka N, Omae M, Ishiyama A, Yoshio T, Hirasawa T, Yamamoto Y, Nagahama M, Takahashi H, Tsuchida T: Study on clinical factors involved in Helicobacter pylori-uninfected, undifferentiated-type early gastric cancer. Digestion 2017; 96: 213–219.
[PubMed]
https://doi.org/10.1159/000481817
20.
Ueyama H, Yao T, Nakashima Y, Hirakawa K, Oshiro Y, Hirahashi M, Iwashita A, Watanabe S: Gastric adenocarcinoma of fundic gland type (chief cell predominant type): proposal for a new entity of gastric adenocarcinoma. Am J Surg Pathol 2010; 34: 609–619.
[PubMed]
https://doi.org/10.1097/PAS.0b013e3181d94d53
21.
Rindi G, Luinetti O, Cornaggia M, Capella C, Solcia E: Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. Gastroenterology 1993: 104: 994–1006.
[PubMed]
22.
Singhi AD, Lazenby AJ, Montgomery EA: Gastric adenocarcinoma with chief cell differentiation: a proposal for reclassification as oxyntic gland polyp/adenoma. Am J Surg Pathol 2012; 36: 1030–1035.
[PubMed]
https://doi.org/10.1097/PAS.0b013e31825033e7
23.
Yamamoto Y, Fujisaki J, Omae M, Hirasawa T, Igarashi M: Helicobacter pylori-negative gastric cancer: Characteristics and endoscopic findings. Dig Endosc 2015; 27: 551–561.
[PubMed]
https://doi.org/10.1111/den.12471
© 2018 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2018
You do not currently have access to this content.